Vise Technologies Inc. Buys Shares of 25,199 Medtronic PLC $MDT

Vise Technologies Inc. purchased a new position in Medtronic PLC (NYSE:MDT) during the 2nd quarter, according to its most recent disclosure with the SEC. The fund purchased 25,199 shares of the medical technology company’s stock, valued at approximately $2,197,000.

Several other hedge funds also recently modified their holdings of the business. Legacy Advisory Services LLC bought a new stake in Medtronic in the first quarter valued at about $541,000. GC Wealth Management RIA LLC boosted its holdings in Medtronic by 20.6% during the second quarter. GC Wealth Management RIA LLC now owns 33,569 shares of the medical technology company’s stock valued at $2,926,000 after purchasing an additional 5,734 shares in the last quarter. Verdence Capital Advisors LLC grew its stake in shares of Medtronic by 22.0% in the 2nd quarter. Verdence Capital Advisors LLC now owns 29,396 shares of the medical technology company’s stock valued at $2,562,000 after purchasing an additional 5,296 shares during the period. World Investment Advisors grew its stake in shares of Medtronic by 1.9% in the 2nd quarter. World Investment Advisors now owns 156,107 shares of the medical technology company’s stock valued at $13,608,000 after purchasing an additional 2,868 shares during the period. Finally, Sivik Global Healthcare LLC raised its holdings in shares of Medtronic by 6.7% in the 2nd quarter. Sivik Global Healthcare LLC now owns 80,000 shares of the medical technology company’s stock worth $6,974,000 after buying an additional 5,000 shares in the last quarter. 82.06% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Medtronic news, Director William R. Jellison bought 2,500 shares of the company’s stock in a transaction on Monday, August 25th. The stock was bought at an average price of $92.37 per share, for a total transaction of $230,925.00. Following the transaction, the director owned 5,000 shares of the company’s stock, valued at approximately $461,850. The trade was a 100.00% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Harry Skip Kiil sold 8,605 shares of the stock in a transaction on Wednesday, September 3rd. The shares were sold at an average price of $91.58, for a total value of $788,045.90. Following the completion of the transaction, the executive vice president directly owned 35,615 shares in the company, valued at approximately $3,261,621.70. This trade represents a 19.46% decrease in their position. The SEC filing for this sale provides additional information. 0.26% of the stock is currently owned by insiders.

Medtronic Stock Up 2.9%

NYSE MDT opened at $95.32 on Wednesday. The stock has a market capitalization of $122.27 billion, a P/E ratio of 26.26, a price-to-earnings-growth ratio of 2.42 and a beta of 0.77. Medtronic PLC has a 52 week low of $79.29 and a 52 week high of $99.37. The company has a debt-to-equity ratio of 0.54, a quick ratio of 1.50 and a current ratio of 2.01. The stock has a fifty day moving average of $94.24 and a 200-day moving average of $90.18.

Medtronic (NYSE:MDT) last issued its quarterly earnings results on Tuesday, August 19th. The medical technology company reported $1.26 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.23 by $0.03. The business had revenue of $8.58 billion for the quarter, compared to analyst estimates of $8.37 billion. Medtronic had a return on equity of 14.61% and a net margin of 13.63%.The firm’s revenue for the quarter was up 7.7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.23 earnings per share. Medtronic has set its FY 2026 guidance at 5.600-5.660 EPS. On average, equities research analysts forecast that Medtronic PLC will post 5.46 EPS for the current year.

Medtronic Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, October 17th. Shareholders of record on Friday, September 26th were paid a $0.71 dividend. The ex-dividend date of this dividend was Friday, September 26th. This represents a $2.84 dividend on an annualized basis and a yield of 3.0%. Medtronic’s dividend payout ratio (DPR) is presently 78.24%.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on MDT. Mizuho boosted their price target on Medtronic from $98.00 to $100.00 and gave the company an “outperform” rating in a research note on Wednesday, July 16th. Daiwa Capital Markets boosted their target price on shares of Medtronic from $101.00 to $104.00 and gave the company a “buy” rating in a research note on Friday, September 12th. The Goldman Sachs Group lowered their target price on shares of Medtronic from $82.00 to $81.00 and set a “sell” rating on the stock in a report on Wednesday, October 1st. Royal Bank Of Canada reissued an “outperform” rating and set a $111.00 price target on shares of Medtronic in a report on Friday, October 10th. Finally, Morgan Stanley reaffirmed an “overweight” rating and set a $107.00 price objective (up from $98.00) on shares of Medtronic in a research note on Tuesday, July 15th. One research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, nine have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $102.82.

About Medtronic

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.